Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. - Wikidata - wikimedia - TriplyDB

Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

http://www.wikidata.org/entity/Q42485941

about

Neoadjuvant therapy in the treatment of breast cancer Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation.Pathogenesis, prevention, diagnosis and treatment of breast cancer.Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.Tumor intrinsic subtype is reflected in cancer-adjacent tissue.Pattern of distant recurrence according to the molecular subtypes in Korean women with breast cancer Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.Analysis of terminal duct lobular unit involution in luminal A and basal breast cancers.Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy.Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice.The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.High TFAP2C/low CD44 expression is associated with an increased rate of pathologic complete response following neoadjuvant chemotherapy in breast cancer.Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.Breast-conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up.Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype.Triple-negative breast cancer: making the most of a misnomer.Management of the axilla in early breast cancer patients in the genomic era.Expanding the Indications for Total Skin-Sparing Mastectomy: Is It Safe for Patients with Locally Advanced Disease?Local therapy for triple-negative breast cancer: a comprehensive review.The CCL5/CCR5 axis promotes metastasis in basal breast cancer.Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer.Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy: A PRISMA-compliant systematic review and meta-analysis.Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population.Effect of statins on breast cancer recurrence and mortality: a review.The evolution of regional nodal irradiation in breast cancer.Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with 177Lu.

P2860

Q27694514-A753D2F7-C14C-4C63-97BA-359263D2AA41 Q33816245-28751E8A-8F68-4405-8151-525F9F6CD6D1 Q34023647-C9D90D63-101E-44ED-84E4-310FECDE7CAA Q34158197-E7DEE68A-3A56-406D-9466-7A5E142E566A Q35605872-D189874B-06DC-4D69-8A3F-3F204304120A Q35624103-7A10AA7D-EC5C-4738-99B7-31FA44276ED6 Q35777113-8F5CFA44-767F-44F8-9937-D4868AE9DF2A Q35901372-B325DB69-3461-4FC4-88BF-C90C07F2D9C3 Q36245392-F59163CC-F2E9-4E55-89A3-01332661DD02 Q36245614-4573771B-A475-459E-83AA-F97E8604D5AD Q36286709-4EB579F1-4543-47AB-9091-5D27A19F33BB Q36546612-0A85F809-663B-4235-BC0E-EEFB9AF094C4 Q36816914-3DF8B2FD-D8CF-4673-8580-76FAAB49A090 Q37172857-3BE163D8-6FB5-4DCA-B26E-4102752A351D Q37214094-0FF09610-E25E-40F7-BB84-07EA04F62420 Q37217746-7018FB59-18B1-409F-9509-FBEF30CFC2E7 Q37288041-80F1E69F-D861-454D-824D-9822B626998C Q37367411-56032E50-DC3C-40A7-BF49-8B85BF8E5526 Q37697506-29990502-B53E-432E-9613-D90D6354E6F9 Q37965397-135A638B-E926-4BFB-8B6A-6CDA2D5EEF6D Q38004606-4174D214-C7F9-4465-AF94-E1F0C206DF37 Q38061094-38D8B75D-CA0F-4072-934C-10F91C6F4B92 Q38546419-3822884F-4DD2-4CF7-8C59-9366A2079236 Q38647008-2C172042-6CA2-4ABE-9C20-7EDE07559E66 Q40725376-1B615951-C9D4-45FE-BF64-87F798312D10 Q44007838-1D9AFF9D-2A73-4F2E-8ADC-3E5D4D58D3F9 Q46429749-23DBD51F-E6F5-402B-B174-4956B5D0BB32 Q46542099-920DDBE5-5E33-47C5-9F19-8328802A48C6 Q47108341-7304A690-024A-41B3-A610-B8FA43D0F096 Q48059157-9F6EF951-4956-407C-A011-AE88ABD5EF95 Q52775601-7A813FBD-A128-4D9C-B1E4-3BE847025EBE

P2860

Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

http://www.wikidata.org/entity/Q42485941

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Impact of breast cancer molecu ...... ocally advanced breast cancer.

@en

Impact of breast cancer molecu ...... ocally advanced breast cancer.

@nl

type

label

Impact of breast cancer molecu ...... ocally advanced breast cancer.

@en

Impact of breast cancer molecu ...... ocally advanced breast cancer.

@nl

prefLabel

Impact of breast cancer molecu ...... ocally advanced breast cancer.

@en

Impact of breast cancer molecu ...... ocally advanced breast cancer.

@nl

P1433

Q42485941-0DAFBFFC-48BE-4996-BA95-2BAFB1FA818A

P1476

Q42485941-462006FD-93F6-4B77-834A-8B5C726923C8

P2093

Q42485941-007966AA-F7DB-40ED-A13B-757628E22322

Q42485941-334DDC79-7B99-46FC-96BC-915F753D4F96

Q42485941-434FE70C-B17B-4CA8-8026-D38B7156FE4D

Q42485941-8A7CA0AA-567D-43DA-B565-B6C2257A57D7

Q42485941-C52BD3FA-C51A-4869-A708-54C73F6A15B7

Q42485941-C53F0BB9-B1C7-4F91-97AA-6BBBBCA782A7

Q42485941-D2918B18-EFBC-4A19-97C0-7ED351880300

Q42485941-DB5217F2-F1A0-4D00-A970-23D1F4DE791A

Q42485941-DEB4507E-A4B5-4B9D-AA1D-90569C493294

P2860

Q42485941-0A0959F5-E49C-4740-B027-29602ECFFDE6

Q42485941-0F6891A2-ECF2-4766-9D22-C2DEDA3C5865

Q42485941-1A09C98F-CAF1-4D2A-ADC1-DC6C2A733CCA

Q42485941-4DCB580F-F186-47CF-8BD9-E015AD03F0FD

Q42485941-59F536DE-2BD0-46D8-A0E7-5E7F40172DFE

Q42485941-5B558ACD-5395-489F-8D37-CB8FB81C3893

Q42485941-5EEEDDB4-F8B8-4C06-A5A2-7BCD0798E449

Q42485941-693C33EE-DB96-4200-A9F5-98AEF379E3D3

Q42485941-9AE8015D-7392-418B-A6A4-AFFBA77A8EBC

Q42485941-9CF1AADE-BA53-4226-99EF-C3B8C1DE5E3D

P2888

Q42485941-7A730F06-36D2-4E75-A842-CC02ED80938B

P304

Q42485941-B5D9A3F2-6CF2-4FD0-8073-9E7A60D70789

P31

Q42485941-24F134C4-CE45-4F4C-9FFD-1F85AA0BC883

P356

Q42485941-CB04071C-0ECC-4A8B-BD2B-E11949DD732B

P433

Q42485941-7AE3BEC1-7CAD-44F5-A14F-1B3AC93EB92C

P478

Q42485941-BE47B2BA-6995-4712-9434-8406D8A28567

P577

Q42485941-7E8CBC99-7215-4764-B86C-5212C61F9806

P6179

Q42485941-6A80698E-0BF1-4906-B890-24B00FC7544F

P698

Q42485941-6B8BA859-8A43-4D43-921F-35CE36CF1070

P921

Q42485941-F74F07FE-FAD4-446B-8C03-28BA8BA20729

P356

S10434-011-1665-8

P1433

Annals of Surgical Oncology

P1476

Impact of breast cancer molecu ...... ocally advanced breast cancer.

@en

P2093

Amy A Drobish

http://www.w3.org/2001/XMLSchema#string

David W Ollila

http://www.w3.org/2001/XMLSchema#string

Dominic T Moore

http://www.w3.org/2001/XMLSchema#string

E Claire Dees

http://www.w3.org/2001/XMLSchema#string

Emily M Burrows

http://www.w3.org/2001/XMLSchema#string

Keith D Amos

http://www.w3.org/2001/XMLSchema#string

Lisa A Carey

http://www.w3.org/2001/XMLSchema#string

Michael O Meyers

http://www.w3.org/2001/XMLSchema#string

Nancy Klauber-Demore

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Repeated observation of breast tumor subtypes in independent gene expression data sets

Supervised risk predictor of breast cancer based on intrinsic subtypes

Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.

Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.

Breast cancer classification and prognosis based on gene expression profiles from a population-based study.

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

P2888

s10434-011-1665-8

P304

2851-2857

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-011-1665-8

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1030105498

http://www.w3.org/2001/XMLSchema#string

P698

21442348

http://www.w3.org/2001/XMLSchema#string

P921